We are conducting clinical development of an oral therapeutic cancer vaccine. We have completed a Phase I clinical trial targeting urothelial carcinoma and are currently conducting a Phase I/IIa clinical trial for malignant pleural mesothelioma.
株式会社イムノロック（本社：神戸市、代表取締役CEO：白川利朗、以下「当社」）は、神戸天然物化学株式会社（本社：神戸市、代表取締役社長：真岡宅哉）及び神戸信用金庫（本店：神戸市、代表理事：西多弘行）を...
[画像1: https://prtimes.jp/i/125161/5/resize/d125161-5-29ba4ba02349f2a0e961-2.png ] 株式会社イムノロック（本社：神戸市、代表取締役CEO：白川利朗、以下「当社」）は、株式会社神戸大学キャピタル（KUC1...
[画像1: https://prtimes.jp/i/125161/3/resize/d125161-3-864079061e220d758061-2.png ] 株式会社イムノロック（本社：神戸市、代表取締役CEO：白川利朗、以下「当社」）は、大阪大学ベンチャーキャピタル株式...
株式会社イムノロック（本社：神戸市、代表取締役CEO：白川利朗、以下「当社」）は、下記を引受先とする第三者割当増資を行い、シードラウンドBとして総額1億400万円を2023年7月に調達したことを報告いたします。...
Development of cancer treatment equipment using optical electromagnetic waves
Some children suffer from learning disabilities and experience difficulties in daily life due to poor eye movement, which makes it difficult to read and to play sports. We are developing an evidence-based system that uses eye tracking and eye movement indexing technologies to assess eye movements and provide training for children who are encountering these eyesight challenges. We are currently deploying this system in municipal consultation centers, elementary schools, and after-school day care centers.
Cerebro Pharma was established in 2020 as an Osaka-based bio-venture with the mission to create a society free of dementia. We focus on research and development of healthcare products and pharmaceuticals specializing in the prevention and improvement of dementia and neurodegenerative diseases, and actively promote collaborative projects with major domestic pharmaceutical companies and academic institutions.
A startup developing a tooth regeneration drug that enables the regeneration of missing teeth in congenital anodontia by utilizing neutralizing antibodies that suppress molecules inhibiting tooth germ growth.
